Sarpogrelate
- Generic Name
- Sarpogrelate
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO6
- CAS Number
- 125926-17-2
- Unique Ingredient Identifier
- 19P708E787
- Background
Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
- Indication
用于改善慢性动脉闭塞症所引起的溃疡、疼痛及冷感等缺血性症状。
Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis.
- Conditions
- AtherosclerosisStroke
- Interventions
- Drug: Traditional administration of Clopidogrel
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Ewha Womans University Seoul Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06424548
Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease
- Conditions
- Arterial Occlusive DiseasesIntermittent Claudication
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 148
- Registration Number
- NCT06046196
- Locations
- 🇰🇷
GangNeung Asan Hospital, Gangneung-si, Gangwon-do, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
- Conditions
- SarpogrelateBlood ViscosityCoronary Artery DiseasePeripheral Arterial Disease
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT05730621
- Locations
- 🇰🇷
The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 1003
- Registration Number
- NCT05083299
- Locations
- 🇰🇷
BuKyung Kim, Busan, Korea, Republic of
Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
- Conditions
- Healthy Individuals
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- University of Karachi
- Target Recruit Count
- 30
- Registration Number
- NCT04941196
- Locations
- 🇵🇰
Center for Bioequivalence Studies and clinical research, Karachi, Sindh, Pakistan
Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 38
- Registration Number
- NCT03947528
- Locations
- 🇰🇷
Daewoong pharmatceutical, Seoul, Korea, Republic of
Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 38
- Registration Number
- NCT03947489
- Locations
- 🇰🇷
Daewoong pharmatceutical, Seoul, Korea, Republic of
A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity
- Conditions
- Peripheral Artery Disease, PAD
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT03509922
- Locations
- 🇰🇷
The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Uijeongbu, Gyeonggido, Korea, Republic of
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
- Conditions
- Peripheral Arterial Disease
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 272
- Registration Number
- NCT02959606
- Locations
- 🇰🇷
Seung-Kee Min,, Seoul, Korea, Republic of
Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02607436
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.